Australia markets closed

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
300.19-5.65 (-1.85%)
At close: 04:00PM EDT
298.00 -2.19 (-0.73%)
Pre-market: 08:36AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close305.84
Open303.11
Bid300.11 x 100
Ask300.28 x 100
Day's range298.31 - 303.51
52-week range211.71 - 329.72
Volume2,281,191
Avg. volume2,659,936
Market cap161.032B
Beta (5Y monthly)0.60
PE ratio (TTM)43.70
EPS (TTM)6.87
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yield9.00 (2.94%)
Ex-dividend date16 May 2024
1y target est293.27
  • Yahoo Finance Video

    Nvidia, advances in cancer research, climate change under Trump: Market Domination

    Nvidia (NVDA) continues to dominate the tech sector as the company's shares move past $1,100. The chip giant earned a boost from Elon Musk, who announced that xAI's supercomputer will run on Nvidia technology. Meanwhile, Tesla (TSLA) shareholders are awaiting an important vote on June 13, which will dictate the fate of Musk's proposed pay package of $56 billion. The American Society of Clinical Oncology (ASCO) will hold its annual meeting in Chicago this week, exploring the latest advancements in the cancer research sector. Tom Steyer, Galvanize Climate Solutions Co-Executive Chair, also joins the show to give insight into the state of climate change mitigation under a possible second Trump presidency. For more expert insight and the latest market action, click here.

  • Yahoo Finance Video

    Tapping into the GLP-1 hype? Consider these pharma stocks.

    Enthusiasm for GLP-1 drugs on Wall Street persists, with Eli Lilly (LLY) committing more than $5.3 billion to expand a plant involved in the production of tirzepatide weight-loss and diabetes injections. Jefferies Biotechnology Managing Director Michael Yee joins Market Domination to explain which biotech companies are hidden gems in the GLP-1 craze on Wall Street. "We have said Amgen (AMGN) is one of the most important large-cap companies that we have been very bullish on. And they, too, will go to phase three with a monthly GLP-1. And we think the data is going to be great the end of the year. There's also smaller companies, like Scholar Rock, SRRK, or Corbis that also have new modalities that are interesting," Yee tells Yahoo Finance. For more on the biotech sector and the upcoming annual conference for The American Society of Clinical Oncology, watch the full interview with Michael Yee here: https://finance.yahoo.com/video/biotech-sector-cancer-vaccines-pd-204711308.html  For more expert insight and the latest market action, click here to watch this full episode of Market Domination. This post was written by Nicholas Jacobino

  • PR Newswire

    AMGEN TO PRESENT INNOVATIVE RESEARCH FROM ITS ROBUST ONCOLOGY PORTFOLIO AT ASCO 2024

    Amgen (NASDAQ:AMGN) today announced the presentation of new data from its broad oncology portfolio at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place from May 31-June 4 in Chicago. The 17 abstracts from Amgen-sponsored and partner-led studies, including one late-breaking oral presentation, demonstrate Amgen's commitment to innovation and meaningfully improving outcomes for people living with difficult-to-treat cancers.